期刊
DIABETES
卷 69, 期 9, 页码 2003-2016出版社
AMER DIABETES ASSOC
DOI: 10.2337/db19-1001
关键词
-
资金
- UAB Diabetes Research Centersponsored pilot and feasibility program - National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases [P30-DK079626]
- UAB Center for Clinical and Translational Science pilot and feasibility program by the NIH Clinical Center [UL1-TR-003096]
- UAB Comprehensive Diabetes Center [R01-HL-128695]
- National Heart, Lung, and Blood Institute [R01-HL-128695]
- National Institute on Aging [R03-AG-058078]
- National Institute of Diabetes and Digestive and Kidney Diseases [R01-DK-112934, R00DK-95975, 1R01-DK-120684, DK-099550]
- National Institute of General Medical Sciences [T32-GM-109780]
Targeting retinoid X receptor (RXR) has been proposed as one of the therapeutic strategies to treat individuals with metabolic syndrome, as RXR heterodimerizes with multiple nuclear receptors that regulate genes involved in metabolism. Despite numerous efforts, RXR ligands (rexinoids) have not been approved for clinical trials to treat metabolic syndrome due to the serious side effects such as hypertriglyceridemia and altered thyroid hormone axis. In this study, we demonstrate a novel rexinoid-like small molecule, UAB126, which has positive effects on metabolic syndrome without the known side effects of potent rexinoids. Oral administration of UAB126 ameliorated obesity, insulin resistance, hepatic steatosis, and hyperlipidemia without changes in food intake, physical activity, and thyroid hormone levels. RNA-sequencing analysis revealed that UAB126 regulates the expression of genes in the liver that are modulated by several nuclear receptors, including peroxisome proliferator-activated receptor alpha and/or liver X receptor in conjunction with RXR. Furthermore, UAB126 not only prevented but also reversed obesity-associated metabolic disorders. The results suggest that optimized modulation of RXR may be a promising strategy to treat metabolic disorders without side effects. Thus, the current study reveals that UAB126 could be an attractive therapy to treat individuals with obesity and its comorbidities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据